Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04089943 · ClinicalTrials.gov registry record · NA
The Role of microRNA-210 in Regulating Oxidative Stress in Patients With PAD
A NA study of Peripheral Arterial Disease and Atherosclerosis, sponsored by University of West Florida.
- Completed
- Registry status
- NA
- Development phase
- 230
- Enrollment target
- 2
- Study locations
NCT04089943: Completed NA study of Peripheral Arterial Disease and Atherosclerosis, sponsored by University of West Florida.
NCT04089943 is a NA study of Peripheral Arterial Disease and Atherosclerosis that has completed, run by University of West Florida. The registered enrollment target is 230 participants, below the 4,203-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04089943, a NA study of Peripheral Arterial Disease and Atherosclerosis, has completed, sponsored by University of West Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 230 participants
- Enrollment target
- 2
- Study locations
Study Summary
MicroRNA-210 (miR-210) can be a potential therapeutic target of patients with peripheral artery disease (PAD). Recent evidence suggests the role of miR-210 and oxidative stress in the pathophysiology of PAD and its association with mitochondrial function, oxidative metabolism, walking distances and quality of life. The protocol evaluates the mechanisms which miR-210 regulates oxidative stress and provides evidence of potential therapeutic strategies.
Primary Outcome
Measure miR-210 gene expression at baseline and after intervention
Conditions Studied
Interventions
- OTHER Control group
- PROCEDURE Revascularization operation
Study Locations (2)
Texas
- UT Austing Dell Medical School - Austin
- Baylor Scott and White - Temple
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2019-09-15 |
| Est. Completion | 2025-08-25 |
| Phase | NA |
What the finished NCT04089943 record still lists
NCT04089943 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, below the 4,203-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (95% lower).
The record links to 4 conditions, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 2 interventions - of which Control group is the first listed.
NCT04089943 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04089943 about?
NCT04089943 is a clinical study titled "The Role of microRNA-210 in Regulating Oxidative Stress in Patients With PAD". MicroRNA-210 (miR-210) can be a potential therapeutic target of patients with peripheral artery disease (PAD). Recent evidence suggests the role of miR-210 and oxidative stress in the pathophysiology of PAD and its association with mitochondrial function, oxidative metabolism, walking distances and ...
What is the current status of trial NCT04089943?
This trial is currently completed. It is a NA study. The enrollment target is 230 participants. The study started on 2019-09-15. Estimated completion is 2025-08-25.
What conditions does trial NCT04089943 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease, Atherosclerosis, Arterial Occlusive Diseases, Vascular Diseases, Peripheral.
What interventions are being tested in trial NCT04089943?
The interventions under investigation include: Control group (OTHER), Revascularization operation (PROCEDURE).
Who is sponsoring clinical trial NCT04089943?
This trial is sponsored by University of West Florida, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04089943 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04089943's enrollment target sits among peer trials
230 20th of 79 higher than 60 of 79 other Peripheral Arterial Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Arterial Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SELUTION4BTK Trial
RECRUITING · NA
-
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
RECRUITING · NA
-
Ultrasound Perfusion Estimation for Assessment of Peripheral Arterial Disease
RECRUITING · NA
-
Prehabilitation and Rehabilitation in PAD
RECRUITING · NA
-
Replexa+ Shortwave Diathermy Device for Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy
RECRUITING · NA
-
Assessment of the Utility of the Pantheris Small Vessel (SV) System
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI